EFMODY 10 MG

מדינה: ישראל

שפה: אנגלית

מקור: Ministry of Health

מרכיב פעיל:

HYDROCORTISONE

זמין מ:

MEDOMIE PHARMA LTD, ISRAEL

קוד ATC:

H02AB09

טופס פרצבטיות:

MODIFIED RELEASE CAPSULES HARD

הרכב:

HYDROCORTISONE 10 MG

מסלול נתינה (של תרופות):

PER OS

סוג מרשם:

Required

תוצרת:

DIURNAL EUROPE B.V., THE NETHERLANDS

איזור תרפויטי:

HYDROCORTISONE

סממני תרפויטית:

Treatment of congenital adrenal hyperplasia (CAH) in adolescents aged 12 years and over and adults

תאריך אישור:

2023-06-15

מאפייני מוצר

1
Efmody-5_10 mg-SPC
Efmody-S P C-0923
PHYSICIAN’S PRESCRIBING INFORMATION
1.
NAME OF THE MEDICINAL PRODUCT
Efmody 5 mg modified-release hard capsules
Efmody 10 mg modified-release hard capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Efmody 5 mg modified-release hard capsules.
Each modified-release hard capsule contains 5 mg hydrocortisone.
Efmody 10 mg modified-release hard capsules.
Each modified-release hard capsule contains 10 mg hydrocortisone.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Modified-release hard capsules.
Efmody 5 mg modified-release hard capsules.
A capsule (approx.19 mm long) with an opaque blue cap and opaque white
body printed with
“CHC 5 mg” containing white to off white granules.
Efmody 10 mg modified-release hard capsules.
A capsule (approx.19 mm long) with an opaque green cap and opaque
white body printed with
“CHC 10 mg” containing white to off white granules.
4.
CLINICAL PARTICULARS
4.1
Therapeutic indications
Treatment of congenital adrenal hyperplasia (CAH) in adolescents aged
12 years and over and adults.
4.2
Posology and method of administration
Posology
Treatment should be initiated by physicians experienced in the
management of CAH.
As maintenance therapy the dose must be individualised according to
the response of the individual
patient. The lowest possible dose should be used.
2
Efmody-5_10 mg-SPC
Efmody-S P C-0923
Monitoring of the clinical response is necessary and patients should
be observed closely for signs that
might require dose adjustment, including changes in clinical status
resulting from remissions or
exacerbations of the disease, changes in electrolytes particularly
hypokalaemia, individual
responsiveness to the medicinal product, and the effect of stress
(e.g. surgery, infection, trauma). As
the treatment has a modified-release profile, blood tests are used to
monitor clinical response,
assessment of the evening dose should be done with a morning blood
test and assessment of the
morning dose should be done with an early